Adjuvant Chemotherapy

Jessica A Hellyer; Heather A Wakelee

doi:10.1016/j.thorsurg.2020.01.003

Adjuvant Chemotherapy

Thorac Surg Clin. 2020 May;30(2):179-185. doi: 10.1016/j.thorsurg.2020.01.003. Epub 2020 Mar 2.

Authors

Jessica A Hellyer¹, Heather A Wakelee²

Affiliations

¹ Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.
² Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address: hwakelee@stanford.edu.

PMID: 32327176
DOI: 10.1016/j.thorsurg.2020.01.003

Abstract

Five-year survival rates for patients with early-stage non-small cell lung cancer have room for improvement. Adjuvant chemotherapy results in a small but significant increase in overall survival at 5 years. Efforts to improve outcomes by intensifying adjuvant treatment, utilizing cancer-specific vaccines or tyrosine kinase inhibitors in unselected patients, have been unsuccessful. In addition to research with immune checkpoint inhibitors that are addressed in a separate article, ongoing studies to personalize adjuvant therapy either by selecting only patients with evidence of minimal residual disease or targeting tumor driver mutations are promising.

Keywords: Adjuvant; Chemotherapy; Targeted agents.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / pathology
Carcinoma, Non-Small-Cell Lung* / therapy
Chemotherapy, Adjuvant* / methods
Chemotherapy, Adjuvant* / trends
Humans
Lung Neoplasms* / pathology
Lung Neoplasms* / therapy
Molecular Targeted Therapy / methods*
Neoplasm Staging
Precision Medicine